David J. Arthur - 03 Jan 2023 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Chief Executive Officer, Director
Signature
/s/Mark Rosenblum, as Attorney-in-Fact
Issuer symbol
SLRX
Transactions as of
03 Jan 2023
Net transactions value
$0
Form type
4
Filing time
05 Jan 2023, 16:33:03 UTC
Previous filing
08 Nov 2022
Next filing
15 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLRX Common Stock Award $0 +20,000 +146% $0.000000 33,719 03 Jan 2023 Direct F1
holding SLRX Common Stock 564 03 Jan 2023 By son
holding SLRX Common Stock 552 03 Jan 2023 By daughter
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 25% of the shares of restricted stock will vest on January 2, 2024, and 1/36 of the remaining shares of restricted stock will vest on monthly anniversary thereafter.